Announcements Trials

Browse Landscape

Status

Recruiting 9 Active not recruiting 4 Withdrawn 1 Completed 1 Available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 5 Pancreatic Neoplasms 3 Melanoma 3 Urinary Bladder Neoplasms 2 Sarcoma 2 Ovarian Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 2 Neoplasms 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Urologic Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Ductal Adenocarcinoma (PDAC) 1 Osteosarcoma 1 Neurofibromatoses 1 Neurofibroma, Plexiform 1 Neuroblastoma 1 Myelodysplastic Syndromes 1 Meningioma 1 Mastocytosis, Systemic 1 Lymphoma, Mantle-Cell 1 Lymphoma 1 Leukemia, Myeloid, Acute 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Available × Desmoid Tumors × 90 days × Clear all

NCT05041036 2026-05-08

Individual Patient Compassionate Use of Nirogacestat

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡